Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "Benefits"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
dewey-ones:"610 - Medicine & health"
dewey-ones:"700 - The arts; fine & decorative arts"
language:"English"
product_txtF_mv:"National Center for Biotechnology Information"
Showing
1
-
15
of
15
Search:
'"Benefits"'
,
query time: 0.01s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
Telehealth for patients with heart failure : a review of the clinical effectiveness, cost-effectiveness and guidelines
Published 2015
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
2
Boston keratoprosthesis for the treatment of corneal blindness : clinical effectiveness and cost-effectiveness
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
3
Peer support for diabetes, heart disease, and HIV/AIDS : a review of the clinical effectiveness, cost-effectiveness, and guidelines
Published 2013
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
4
Telehealth for patients with hypertension, coronary artery disease or implantable cardiac devices : a review of the clinical effectiveness, cost-effectiveness and guidelines
Published 2016
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
5
CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
6
CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
7
CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication : adult patients with active psoriatic arthritis (PsA) who have respon...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
8
CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication : adult patients with active psoriatic arthritis (PsA) who have respon...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
9
CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
10
CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.
Published 2017
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
11
Bioabsorbable stents for adults with coronary artery disease : a review of the clinical effectiveness, cost-effectiveness, and guidelines
Published 2013
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
12
CADTH Canadian Drug Expert Committee recommendation: Rivaroxaban (Xarelto -- Bayer Inc.) : indication : coronary artery disease with or without peripheral artery disease
Published 2018
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
13
CADTH Canadian Drug Expert Committee recommendation: Rivaroxaban (Xarelto -- Bayer Inc.) : indication : coronary artery disease with or without peripheral artery disease
Published 2018
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
14
Pharmacoeconomic review report: Rivaroxaban (Xarelto) (Bayer Inc.) : indication : in combination with 75 mg to 100 mg acetylsalicylic acid (ASA), for the prevention of stroke, myoc...
Published 2019
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Read Now
15
Pharmacoeconomic review report: Rivaroxaban (Xarelto) (Bayer Inc.) : indication : in combination with 75 mg to 100 mg acetylsalicylic acid (ASA), for the prevention of stroke, myoc...
Published 2019
CADTH
Subjects:
“
...Cost-
Benefit
Analysis...
”
Back
Narrow Search
Remove Filters
Clear Filter
Classification: 610 - Medicine & health
Clear Filter
Classification: 700 - The arts; fine & decorative arts
Clear Filter
Language: English
Clear Filter
Collection: National Center for Biotechnology Information
Year of Publication
From:
To:
Classification
610 - Medicine & health
700 - The arts; fine & decorative arts
330 - Economics
9
140 - Specific philosophical schools
2
580 - Plants (Botany)
1
Language
English
Collection
National Center for Biotechnology Information
Author
Canadian Agency for Drugs and Technologies in Health
13
CADTH Canadian Drug Expert Committee
8
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=dewey-ones%3A%22610+-+Medicine+%26+health%22&filter%5B%5D=dewey-ones%3A%22700+-+The+arts%3B+fine+%26+decorative+arts%22&filter%5B%5D=language%3A%22English%22&filter%5B%5D=product_txtF_mv%3A%22National+Center+for+Biotechnology+Information%22&lookfor=%22Benefits%22&type=Subject
Send by Email
×
Loading...